Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that adenosine significantly increased the proportion of thick hair in Caucasian men with androgenetic alopecia, with no reported adverse effects.

This article discusses the hypothesis that mechanisms driving androgenic alopecia may reduce the risk and proliferation of prostate cancer by increasing prostaglandin D2 levels but presents no new clinical findings.

This study found that patients with androgenetic alopecia had a higher incidence of metabolic syndrome and benign prostatic hyperplasia compared to those without the condition.

This study found that scalp hypothermia effectively prevented chemotherapy-induced alopecia in 57.3% of breast cancer patients, with side effects such as a feeling of cold and slight headaches reported in 16% of cases.

In this study, the combination of scalp cooling therapy and a scalp lotion containing DHL-HisZnNa demonstrated a 91.3% hair recovery rate among breast cancer patients undergoing certain chemotherapy regimens, with no serious adverse events reported.

This study evaluated high-dose oral minoxidil treatment in 57 patients with androgenetic alopecia and found it improved hair density by 10-30% in most cases, but 24.6% experienced adverse effects like hypertrichosis and tachycardia, indicating further research is needed to optimize safety and efficacy.

In this study conducted at Saveetha Dental College, researchers found that the severity of male androgenetic alopecia, as graded by Norwood's classification, increased with age, although other factors such as genetic or hormonal influences were not assessed.

This case report involved a premenopausal woman with rapidly progressing virilizing symptoms caused by a rare sertoliform endometrioid carcinoma of the ovary. Following surgical intervention, her symptoms improved, highlighting the importance of recognizing virilizing symptoms as potential indicators of low-grade ovarian malignancies in similar cases.

This study found that trichoscopy can confirm the diagnosis and assess the clinical severity of female androgenetic alopecia, correlating specific features with different severity grades.

Topical 5α-reductase inhibitor helps counteract hair loss and stabilize it.

This study found that topical cetirizine 1% significantly improved hair density and diameter in patients with androgenetic alopecia, with patients tolerating the treatment well.

This study found that rosemary oil and minoxidil 2% both increased hair count equally in patients with androgenetic alopecia after 6 months, with more scalp itching seen in the minoxidil group.

This study found that PRP therapy was effective and safe for treating androgenic alopecia, promoting 30% hair growth and showing antimicrobial activity against certain bacteria in affected patients.

This study observed that a tacrolimus solution (0.1%) applied to the scalp was effective and well-tolerated for treating inflammatory scalp conditions, with 72.7% of patients showing an excellent response after 2 months of treatment, which persisted after 6 months.

This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.

This review examines the clinical presentation of alopecia areata in children and compares it to adult-onset cases, noting that data on pediatric cases is scarce and often varies, with reported onset typically between ages 6 and 12.

This article examines the potential of using oral minoxidil as an adjuvant treatment for patients with severe alopecia areata who do not respond to increased doses of Janus kinase inhibitors, but provides no new clinical results.

This review concluded that low-dose oral minoxidil is an effective and well-tolerated treatment for male androgenetic alopecia, with significant hair density improvements and manageable side effects.

In this retrospective study, oral minoxidil was found to improve the density of the frontotemporal hairline in 45.1% of patients with frontal fibrosing alopecia, with some also experiencing eyebrow and eyelash growth; however, adverse effects such as hypertrichosis were noted in 33.6% of the participants.

This study found that among women with hirsutism, the most common type of non-scarring alopecia observed was androgenetic alopecia with telogen effluvium.

In this study, among individuals with androgenic alopecia, stromal vascular fraction injections led to greater clinical improvement and hair density increases compared to nanofat injections, with 26.7% of participants showing great improvement versus 6.7% in the nanofat group after six months.

This study reported that targeted anticancer therapies are associated with an increased risk of alopecia compared to placebo, although the risk was lower compared to chemotherapy.

This study found that male Indian patients under 30 with early androgenetic alopecia were more likely to have metabolic syndrome compared to age-matched controls.

This study observed that topical dinitrochlorobenzene was significantly more effective than topical betamethasone in treating patients with alopecia areata, with 53.3% achieving excellent hair regrowth compared to 13.3% using betamethasone.

This study examined young Ukrainian men with alopecia areata and found that different severities of the condition were associated with distinct clinical and trichoscopic features, such as variations in hair loss, stress levels, and nail involvement, among others.

This review of interventions for alopecia areata found no significant treatment benefits for hair growth compared to placebo, indicating a need for larger, well-conducted studies.

This study identified two distinct histological patterns in permanent alopecia following bone marrow transplantation, suggesting links to myeloablative chemotherapy and chronic graft-versus-host disease.

This study found that intralesional corticosteroids remain the preferred treatment for alopecia areata with limited involvement, while platelet-rich plasma showed promise, particularly in children and extensive cases.

This chapter provides an overview of chemotherapy-induced alopecia, discussing its biological and clinical aspects, current experimental models and treatments, and calls for improved understanding to prevent and manage it.

Men with CCCA often face delayed diagnosis and severe hair loss, highlighting the need for earlier recognition and treatment.